CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
usx:crsp Blog Post1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
usx:gild usx:crsp usx:blue usx:ntla Blog PostIf You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
usx:crsp Blog PostThis 1 Problem Could Sink at Least 4 Gene-Editing Stocks
usx:edit usx:crsp usx:blue usx:ntla Blog PostWall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.
usx:crsp Blog Post